Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized withdrawal study of ampreloxetine for symptomatic neurogenic orthostatic hypotension in multiple system atrophy
MOH_2024-02-21_013144Phase 3Recruiting
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH) and multiple system atrophy (MSA) (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Change in composite OHSA score at Week 8 during the double-blind randomized withdrawal period. Started Feb 2024; status: recruiting.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)multiple system atrophy (MSA)
Beyond the preview
Go deeper on MOH_2024-02-21_013144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-21_013144.